A prespecified SUMMIT analysis finds tirzepatide reduces heart-failure events in obese HFpEF regardless of diabetes status, despite less weight loss with diabetes. PICO summary and commentary.
Browsing: GLP-1 Receptor Agonists
📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context GLP-1 receptor…
A SURMOUNT-1 analysis finds tirzepatide improves insulin sensitivity (mostly via weight loss) and beta-cell function (mostly drug-driven) in obesity without diabetes. PICO summary and commentary.
A SURMOUNT-1 analysis finds 90% of early non-responders to tirzepatide still reached 5% weight loss by week 72, supporting extending treatment. PICO summary and commentary.
A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.
A phase IV randomized trial in 90 adults with type 2 diabetes found dapagliflozin plus exenatide augmented beta-cell function and insulin sensitivity above either agent alone, on surrogate OGTT measures. PICO summary and expert commentary.
An EXSCEL mediation analysis finds conventional risk-factor changes explain only part of exenatide’s cardiovascular benefit and do not mediate its mortality effect. PICO summary and commentary.
A post-hoc analysis finds exenatide does not change inflammatory or metabolic biomarkers in alcohol use disorder, despite raised baseline inflammation. PICO summary and commentary.
A mechanistic trial finds dapagliflozin plus exenatide augments beta-cell function and insulin sensitivity more than either alone in type 2 diabetes. PICO summary and commentary.
Summary: In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c, TIR, TyG), reduced body…